{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T02:08:30Z","timestamp":1781402910719,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Von Hippel-Lindau disease (VHL disease) is a hereditary cancer predisposition syndrome caused by mutations of the von Hippel-Lindau tumor suppressor gene. The gene product, pVHL, regulates the level of proteins that play a central role in protecting cells against hypoxia. Clinical hallmarks of von Hippel-Lindau disease are the development of central nervous system hemangioblastomas, renal cell carcinoma, pheochromocytoma, neuroendocrine tumors and endolymphatic sac tumors.<\/jats:p>\n          <jats:p>In this article the case of a 38-year old hemodialyzed patient who became ill with acute myeloid leukemia (AML) three years after being diagnosed with von Hippel-Lindau disease is presented.<\/jats:p>\n          <jats:p>After cytostatic treatment the patient went into complete hematologic remission but there was still residual disease at the genetic level. After consolidation therapy patient developed bone marrow aplasia and severe pneumonia. Despite intensive treatment the patient died from acute respiratory failure.<\/jats:p>\n          <jats:p>In this paper we present for the first time a case of von Hippel-Lindau disease associated with acute myeloid leukemia. No evidence of relationship between VHL disease and blood cancers has been demonstrated so far. Despite the fact that there is an increased risk of cancer development in hemodialyzed patients, cancer is a relatively rare cause of death in the dialysed population, and the most common malignancies are genitourinary cancers. It seems likely that development of acute myeloid leukemia in patient with VHL disease can be related to epigenetic alterations of the VHL gene, but further studies are needed.<\/jats:p>","DOI":"10.1186\/1897-4287-11-11","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T12:14:46Z","timestamp":1377173686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Acute myeloid leukemia in a 38-year-old hemodialyzed patient with von Hippel-Lindau disease"],"prefix":"10.1186","volume":"11","author":[{"given":"Katarzyna","family":"Labno-Kirszniok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Nieszporek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Wiecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lubinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,22]]},"reference":[{"issue":"283","key":"450_CR1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","volume":"77","author":"ER Maher","year":"1990","unstructured":"Maher ER, Yates JR, Harries R, et al.: Clinical features and natural history of von Hippel-Lindau disease. Quart J Med 1990,77(283):1151\u20131163.","journal-title":"Quart J Med"},{"issue":"6","key":"450_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher ER, Neumann HP, Richard S: Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet 2011,19(6):617\u2013623. 10.1038\/ejhg.2010.175","journal-title":"Eur J Hum Genet"},{"issue":"7","key":"450_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/jmg.28.7.443","volume":"28","author":"ER Maher","year":"1991","unstructured":"Maher ER, Iselius L, Yates JR, et al.: Von Hippel-Lindau disease: a genetic study. J Med Genet 1991,28(7):443\u2013447. 10.1136\/jmg.28.7.443","journal-title":"J Med Genet"},{"issue":"5112","key":"450_CR4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif F, Tory K, Gnarra J, et al.: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993,260(5112):1317\u20131320. 10.1126\/science.8493574","journal-title":"Science"},{"issue":"11","key":"450_CR5","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/hmg\/4.11.2139","volume":"4","author":"FM Richards","year":"1995","unstructured":"Richards FM, Payne SJ, Zbar B, Affara NA, et al.: Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet 1995,4(11):2139\u20132143. 10.1093\/hmg\/4.11.2139","journal-title":"Hum Mol Genet"},{"issue":"9374","key":"450_CR6","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","volume":"361","author":"RR Lonser","year":"2003","unstructured":"Lonser RR, Glenn GM, Walther M, et al.: Von Hippel-Lindau disease. Lancet 2003,361(9374):2059\u20132067. 10.1016\/S0140-6736(03)13643-4","journal-title":"Lancet"},{"issue":"6","key":"450_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.1365-2796.1998.00337.x","volume":"243","author":"S Richard","year":"1998","unstructured":"Richard S, Campello C, Thillandier L, et al.: Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group. J Intern Med 1998,243(6):547\u2013553. 10.1046\/j.1365-2796.1998.00337.x","journal-title":"J Intern Med"},{"issue":"2","key":"450_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/jmg.33.2.120","volume":"33","author":"IR Maddock","year":"1996","unstructured":"Maddock IR, Moran A, Maher ER, et al.: A genetic register for von Hippel-Lindau disease. J Med Genet 1996,33(2):120\u2013127. 10.1136\/jmg.33.2.120","journal-title":"J Med Genet"},{"key":"450_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, Wiesener MS, Chang GW, et al.: The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 1999, 399: 271\u2013275. 10.1038\/20459","journal-title":"Nature"},{"issue":"Pt 6","key":"450_CR10","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","volume":"589","author":"W Jelkmann","year":"2011","unstructured":"Jelkmann W: Regulation of erythropoietin production. J Physiol 2011,589(Pt 6):1251\u20131258.","journal-title":"J Physiol"},{"issue":"24","key":"450_CR11","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","volume":"22","author":"WY Kim","year":"2004","unstructured":"Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 2004,22(24):4991\u20135004. 10.1200\/JCO.2004.05.061","journal-title":"J Clin Oncol"},{"key":"450_CR12","first-page":"453","volume":"1","author":"Y Jiang","year":"2003","unstructured":"Jiang Y, Zhang W, Kondo K, et al.: Gene Expression Profiling in a Renal Cell Carcinoma Cell Line: Dissecting VHL and Hypoxia- Dependent Pathways. Mol Cancer Res 2003, 1: 453\u2013462.","journal-title":"Mol Cancer Res"},{"key":"450_CR13","doi-asserted-by":"publisher","first-page":"6297","DOI":"10.1038\/sj.onc.1204012","volume":"19","author":"CC Wykoff","year":"2000","unstructured":"Wykoff CC, Pugh CW, Maxwell PH, et al.: Identification of novel hypoxia dependent and independent target genes of the von Hippel- Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000, 19: 6297\u20136305. 10.1038\/sj.onc.1204012","journal-title":"Oncogene"},{"key":"450_CR14","doi-asserted-by":"publisher","first-page":"43611","DOI":"10.1074\/jbc.M107880200","volume":"276","author":"H Okuda","year":"2001","unstructured":"Okuda H, Saitoh K, Hirai S, et al.: The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem 2001, 276: 43611\u201343617. 10.1074\/jbc.M107880200","journal-title":"J Biol Chem"},{"key":"450_CR15","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1074\/jbc.M108269200","volume":"277","author":"Z Li","year":"2002","unstructured":"Li Z, Na X, Wang D, et al.: Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem 2002, 277: 4656\u20134662. 10.1074\/jbc.M108269200","journal-title":"J Biol Chem"},{"key":"450_CR16","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1073\/pnas.0436037100","volume":"100","author":"AV Kuznetsova","year":"2003","unstructured":"Kuznetsova AV, Meller J, Schnell PO, et al.: Von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci U S A 2003, 100: 2706\u20132711. 10.1073\/pnas.0436037100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"450_CR17","doi-asserted-by":"publisher","first-page":"39887","DOI":"10.1074\/jbc.M205040200","volume":"277","author":"MI Zhou","year":"2002","unstructured":"Zhou MI, Wang H, Ross JJ, et al.: The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1. J Biol Chem 2002, 277: 39887\u201339898. 10.1074\/jbc.M205040200","journal-title":"J Biol Chem"},{"key":"450_CR18","doi-asserted-by":"publisher","first-page":"11035","DOI":"10.1073\/pnas.0500757102","volume":"102","author":"MI Zhou","year":"2005","unstructured":"Zhou MI, Foy RL, Chitalia VC, et al.: Jade-1, a candidate renal tumor suppressor that promotes apoptosis. Proc Natl Acad Sci USA 2005, 102: 11035\u201311040. 10.1073\/pnas.0500757102","journal-title":"Proc Natl Acad Sci USA"},{"key":"450_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/ng1297-399","volume":"17","author":"The Finnish-German APECED Consortium","year":"1997","unstructured":"The Finnish-German APECED Consortium: An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997, 17: 399\u2013403. 10.1038\/ng1297-399","journal-title":"Nat Genet"},{"key":"450_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ng1097-146","volume":"17","author":"RJ Gibbons","year":"1997","unstructured":"Gibbons RJ, Bachoo S, Picketts DJ, et al.: Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domain. Nat Genet 1997, 17: 146\u2013148. 10.1038\/ng1097-146","journal-title":"Nat Genet"},{"key":"450_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ng1297-393","volume":"17","author":"K Nagamine","year":"1997","unstructured":"Nagamine K, Peterson P, Scott HS, et al.: Positional cloning of the APECED gene. Nat Genet 1997, 17: 393\u2013398. 10.1038\/ng1297-393","journal-title":"Nat Genet"},{"key":"450_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S0037-1963(00)90017-9","volume":"37","author":"Y Hayashi","year":"2000","unstructured":"Hayashi Y: The molecular genetics of recurring chromosome abnormalities in acute myeloid leukemia. Semin Hematol 2000, 37: 368\u2013380. 10.1016\/S0037-1963(00)90017-9","journal-title":"Semin Hematol"},{"key":"450_CR23","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/0008-5472.CAN-03-0884","volume":"64","author":"MI Zhou","year":"2004","unstructured":"Zhou MI, Wang H, Foy RL, et al.: Tumor Suppressor von Hippel-Lindau (VHL) Stabilization of Jade-1 Protein Occurs through Plant Homeodomains and is VHL Mutation Dependent. Cancer Res 2004, 64: 1278\u20131286. 10.1158\/0008-5472.CAN-03-0884","journal-title":"Cancer Res"},{"key":"450_CR24","doi-asserted-by":"publisher","first-page":"9737","DOI":"10.1073\/pnas.92.21.9737","volume":"92","author":"V Saha","year":"1995","unstructured":"Saha V, Chaplin T, Gregorini A, et al.: The leukemi aassociated- protein (LAP) domain, a cysteine-rich motif, is present in a wide range of proteins, including MLL, AF10, and MLLT6 proteins. Proc Natl Acad Sci USA 1995, 92: 9737\u20139741. 10.1073\/pnas.92.21.9737","journal-title":"Proc Natl Acad Sci USA"},{"key":"450_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/gcc.2870130202","volume":"13","author":"OA Bernard","year":"1995","unstructured":"Bernard OA, Berger R: Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Gene Chromosome Canc 1995, 13: 75\u201385. 10.1002\/gcc.2870130202","journal-title":"Gene Chromosome Canc"},{"key":"450_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov AV, Armstrong SA: MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007, 7: 823\u2013833.","journal-title":"Nat Rev Cancer"},{"key":"450_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000013314","volume":"18","author":"S Vamvakas","year":"1998","unstructured":"Vamvakas S, Bahner U, Heidland A: Cancer in end-stage renal disease: potential factors involved. Am J Nephrol 1998, 18: 89\u201395. 10.1159\/000013314","journal-title":"Am J Nephrol"},{"issue":"6","key":"450_CR28","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/sj.leu.2405053","volume":"22","author":"L Benetatos","year":"2008","unstructured":"Benetatos L, Dasoula A, Syed N, et al.: Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes. Leukemia 2008,22(6):1293\u20131295. 10.1038\/sj.leu.2405053","journal-title":"Leukemia"},{"issue":"2","key":"450_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2009-07-232868","volume":"115","author":"M Kanduri","year":"2010","unstructured":"Kanduri M, Cahill N, Goransson H, et al.: Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 2010,115(2):296\u2013305. 10.1182\/blood-2009-07-232868","journal-title":"Blood"},{"issue":"2","key":"450_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2217\/epi.12.13","volume":"4","author":"K Banno","year":"2012","unstructured":"Banno K, Kisu I, Yanokura M, Masuda K: Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics 2012,4(2):147\u2013162. 10.2217\/epi.12.13","journal-title":"Epigenomics"},{"key":"450_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/sj.ki.5001548","volume":"70","author":"M Ando","year":"2006","unstructured":"Ando M, Shibuya A, Tsuchiya K, et al.: Reduced expression of Toll-like receptor 4 contributes to impaired cytokine response of monocytes in uremic patients. Kidney Int 2006, 70: 358\u2013362. 10.1038\/sj.ki.5001548","journal-title":"Kidney Int"},{"key":"450_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/ndt\/gfl519","volume":"22","author":"MA Verkade","year":"2007","unstructured":"Verkade MA, Van Druningen CJ, Vaessen LM, et al.: Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease. Nephrol Dial Transplant 2007, 22: 128\u2013138.","journal-title":"Nephrol Dial Transplant"},{"key":"450_CR33","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1093\/ndt\/gfg330","volume":"18","author":"K Anding","year":"2003","unstructured":"Anding K, Gross P, Rost JM, et al.: The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant 2003, 18: 2067\u20132073. 10.1093\/ndt\/gfg330","journal-title":"Nephrol Dial Transplant"},{"key":"450_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1525-139X.2007.00283.x","volume":"20","author":"T Eleftheriadis","year":"2007","unstructured":"Eleftheriadis T, Antoniadi G, Liakopoulos V, et al.: Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007, 20: 440\u2013451. 10.1111\/j.1525-139X.2007.00283.x","journal-title":"Semin Dial"},{"key":"450_CR35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S0272-6386(98)70148-9","volume":"32","author":"J Bergstr\u00f6m","year":"1998","unstructured":"Bergstr\u00f6m J, Lindholm B: Malnutrition, cardiac disease and mortality: An integrated point of view. Am J Kidney Dis 1998, 32: 834\u2013841. 10.1016\/S0272-6386(98)70148-9","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"450_CR36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/ki.2010.196","volume":"78","author":"SM Kinsella","year":"2010","unstructured":"Kinsella SM, Coyle JP, Long EB, et al.: Maintenance hemodialysis patients have high cumulative radiation exposure. Kidney Int 2010,78(8):789\u2013793. 10.1038\/ki.2010.196","journal-title":"Kidney Int"},{"key":"450_CR37","volume-title":"Health Risks from Exposure to Low Levels of Ionizing Radiation. BEIR VII Phase 2","author":"National Research Council","year":"2006","unstructured":"National Research Council: Health Risks from Exposure to Low Levels of Ionizing Radiation. BEIR VII Phase 2. Washington DC: National Academies Press; 2006."},{"key":"450_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0140-6736(99)06154-1","volume":"354","author":"P Maisonneuve","year":"1999","unstructured":"Maisonneuve P, Agodoa L, Gellert R, et al.: Cancer in end stage renal disease patients undergoing dialysis: Results from an international collaborative study. Lancet 1999, 354: 93\u201399. 10.1016\/S0140-6736(99)06154-1","journal-title":"Lancet"},{"issue":"1","key":"450_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/01.ASN.0000039608.81046.81","volume":"14","author":"JH Stewart","year":"2003","unstructured":"Stewart JH, Buccianti G, Agodoa L, et al.: Cancers of the Kidney and Urinary Tract in Patients on Dialysis for End-Stage Renal Disease: Analysis of Data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003,14(1):197\u2013207. 10.1097\/01.ASN.0000039608.81046.81","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"450_CR40","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1093\/ndt\/gfp331","volume":"24","author":"JH Stewart","year":"2009","unstructured":"Stewart JH, Vajdic CM, Van Leewen MT, et al.: The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 2009,24(10):3225\u20133231. 10.1093\/ndt\/gfp331","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"450_CR41","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2215\/CJN.03931106","volume":"2","author":"JL Holley","year":"2007","unstructured":"Holley JL: Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol 2007,2(3):604\u2013610. Epub 2007 Mar 14 10.2215\/CJN.03931106","journal-title":"Clin J Am Soc Nephrol"},{"key":"450_CR42","first-page":"1199","volume":"19","author":"JD Eneman","year":"2005","unstructured":"Eneman JD: Cancer management in patients with endstage renal disease. Oncology 2005, 19: 1199\u20131212. discussion 1212\u20131214","journal-title":"Oncology"},{"key":"450_CR43","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1089\/thy.2005.15.1321","volume":"15","author":"JP Holst","year":"2005","unstructured":"Holst JP, Burman KD, Atkins F, et al.: Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid 2005, 15: 1321\u20131331. 10.1089\/thy.2005.15.1321","journal-title":"Thyroid"},{"issue":"5","key":"450_CR44","first-page":"2566","volume":"46","author":"M D\u2019Incalci","year":"1986","unstructured":"D\u2019Incalci M, Rossi C, Zucchetti M, et al.: Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986,46(5):2566\u20132571.","journal-title":"Cancer Res"},{"issue":"2","key":"450_CR45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/BF02983222","volume":"77","author":"M Takeuchi","year":"2003","unstructured":"Takeuchi M, Yamauchi T, Yoshida I, et al.: Pharmacokinetics of a standard dose of cytarabine in a patient with acute promyelocytic leukemia undergoing continuous ambulatory peritoneal dialysis. Int J Hematol 2003,77(2):196\u2013198. 10.1007\/BF02983222","journal-title":"Int J Hematol"},{"issue":"4","key":"450_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s12185-008-0171-7","volume":"88","author":"LH Lindner","year":"2008","unstructured":"Lindner LH, Ostermann H, Hiddemann W, et al.: AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity. Int J Hematol 2008,88(4):381\u2013386. 10.1007\/s12185-008-0171-7","journal-title":"Int J Hematol"},{"issue":"6281","key":"450_CR47","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1136\/bmj.282.6281.1999","volume":"282","author":"K Farrington","year":"1981","unstructured":"Farrington K, Miller P, Varghese Z, et al.: Vitamin A toxicity and hypercalcaemia in chronic renal failure. Br Med J (Clin Res Ed) 1981,282(6281):1999\u2013200. 10.1136\/bmj.282.6281.1999","journal-title":"Br Med J (Clin Res Ed)"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1897-4287-11-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1897-4287-11-11\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1897-4287-11-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1897-4287-11-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:35:09Z","timestamp":1630546509000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/1897-4287-11-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,22]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1186\/1897-4287-11-11","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,22]]},"assertion":[{"value":"31 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"11"}}